Meeting Overview - The fifth board meeting of Zhejiang Sitaili Pharmaceutical Co., Ltd. was held on August 28, 2025, combining in-person and communication methods for voting [1] - All 7 directors attended the meeting, with some participating via communication [1] - The meeting was convened and presided over by Chairman Hu Jian [1] - The meeting complied with the relevant laws, regulations, and the company's articles of association [1] Resolutions Passed - The board approved the "2025 Half-Year Report (Full Text and Summary)" with a unanimous vote of 7 in favor [2] - The board approved the "2025 Half-Year Special Report on the Storage and Use of Raised Funds," also with a unanimous vote of 7 in favor [2] - The board approved the "2025 Mid-Year Profit Distribution Plan," with a unanimous vote of 7 in favor [2] - The board approved the "2025 Quality Improvement and Efficiency Enhancement Action Plan's Half-Year Evaluation Report," with a unanimous vote of 7 in favor [3] - The board approved the proposal to establish the "Information Disclosure Postponement and Exemption Management System," with a unanimous vote of 7 in favor [3] - The board approved the proposal for the sale of equity in an associated company, with a unanimous vote of 7 in favor, aimed at optimizing asset structure and increasing operational funds [3]

证券代码：603520 证券简称：司太立 公告编号：2025-041 浙江司太立制药股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 09 月 09 日 （星期二） 至 09 月 15 日 （星 期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目 或通过公司邮箱 stl@starrypharma.com 进行提问。公司将在说明会 上对投资者普遍关注的问题进行回答。 浙江司太立制药股份有限公司（以下简称"公司"）已于 2025 年 8 月 29 日发布公司 2025 年半年度报告，为便于广大投资者更全面深 入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 09 月 16 日 （星期二） 13:00-14:00 举行 2025 年半年度业绩说 明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半 （三） 会议召开方式：上证路演 ...

Core Viewpoint - The company plans to sell its stake in Shanghai Yanno Pharmaceutical Technology Co., Ltd. to Fosun Wanbang for a consideration of 66,441,644 yuan, which corresponds to approximately 9.87% of Yanno's registered capital [4][7][19]. Group 1: Company Overview - Zhejiang Sitaili Pharmaceutical Co., Ltd. is involved in the pharmaceutical industry and is focusing on optimizing its asset structure and increasing operational liquidity through this transaction [8][26]. - The company aims to enhance its core competitiveness by concentrating on its main business after the sale [8][26]. Group 2: Financial Data - The company reported a net profit attributable to shareholders of 29,135,500 yuan for the first half of 2025, with a parent company net profit of 65,222,202.48 yuan [56]. - The proposed cash dividend distribution is 0.5 yuan per 10 shares, amounting to a total of 21,920,494.05 yuan based on the total share capital of 438,409,881 shares as of June 30, 2025 [57][56]. Group 3: Transaction Details - The transaction involves the transfer of 740,001 yuan of registered capital, and the company will no longer hold any equity in Yanno after the completion of this transaction [4][13]. - The transfer price is based on the company's actual investment cost plus an annualized return of 10% from the date of investment to the expected delivery date [19][27]. Group 4: Approval and Conditions - The transaction was approved by the company's board of directors on August 28, 2025, and does not require shareholder meeting approval [6][9]. - The completion of the transaction is subject to certain conditions, including obtaining regulatory approval for a specific product from the National Medical Products Administration [22][24].

（文章来源：证券日报） 证券日报网讯 8月28日晚间，司太立发布公告称，公司第五届董事会第十七次会议审议通过了《公司 2025年半年度报告（全文及摘要）》等多项议案。 ...

证券日报网讯 8月28日晚间，司太立发布公告称，公司第五届监事会第十五次会议审议通过了《公司 2025年中期利润分配预案》等多项议案。 （文章来源：证券日报） ...

Group 1 - The company reported a revenue of 1.398 billion yuan for the first half of 2025, representing a year-on-year increase of 5.06% [1] - The net profit attributable to shareholders reached 29.14 million yuan, showing a year-on-year growth of 27.24% [1] - The net profit excluding non-recurring items was 27.28 million yuan, which is a year-on-year increase of 34.28% [1] - The basic earnings per share were 0.07 yuan [1] Group 2 - The company plans to distribute a cash dividend of 0.5 yuan (including tax) for every 10 shares to all shareholders [1]

Group 1 - The company reported a revenue of 1.398 billion yuan for the first half of the year, representing a year-on-year growth of 5.06% [1] - The net profit attributable to shareholders of the listed company was 29.1355 million yuan, showing a year-on-year increase of 27.24% [1] - The basic earnings per share were 0.07 yuan per share [1]

(一) 实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意浙江司太立制药股份有限公司向特定对象发行 股票注册的批复》（证监许可〔2024〕373 号），本公司由主承销商国泰海通证券股份有限 公司采用非公开发行方式，向特定对象发行人民币普通股 9,589.54 万股，发行价格 9.75 元/股，募集资金总额为人民币 93,498.00 万元，坐扣承销和保荐费用 458.76 万元后的募集 资金为 93,093.24 万元，已由主承销商国泰海通证券股份有限公司于 2024 年 5 月 30 日汇入 本公司募集资金监管账户。另减除申报会计师费、律师费等与发行权益性证券直接相关的新 增外部费用 259.99 万元后，公司本次募集资金净额为 92,779.24 万元。上述募集资金到位 情况业经天健会计师事务所（特殊普通合伙）验证，并由其出具《验资报告》（天健验〔2024〕 199 号）。 (二) 募集资金使用和结余情况 浙江司太立制药股份有限公司 关于 2025 年半年度募集资金存放与使用情况的专项报告 根据中国证券监督管理委员会《上市公司募集资金监管规则》（证监会公告〔2025〕10 号）和上海证券 ...

证券代码：603520 证券简称：司太立 公告编号：2025-040 浙江司太立制药股份有限公司 关于出售参股公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、交易概述 （一）基本情况 浙江司太立制药股份有限公司（以下简称"公司"或"本公司"）拟与复星 万邦（江苏）医药集团有限公司（以下简称"复星万邦"）签署《股权转让协议》 公司拟与复星万邦签署《股权转让协议》，在满足协议所约定先决条件 的前提下，以 66,441,644 元的对价向复星万邦转让所持有的研诺医药 注册资本 740,001 元对应的股权转让（约占当前研诺医药注册资本总额 的 9.8672%；如研诺医药后续发生增资扩股等事件，届时本公司持股比 例以上述注册资本所对应的实际股比为准）。预计本次交易完成后，本 公司将不再持有研诺医药股权。 本次交易不构成关联交易，不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。 本次交易经公司第五届董事会第十七次会议审议通过，本次交易无需提 交股东大会审议。 本次股权转让协议设定先决条件， ...

浙江司太立制药股份有限公司 2025 年"提质增效重回报"行动方案的半年度评估报告 浙江司太立制药股份有限公司 一、聚焦核心主业，提质增效促发展 公司经过二十多年来在医药领域深耕细作，已形成以造影剂、喹诺酮、CDMO 为主业，中间体、原料药、制剂一体化发展，国内、国际两翼齐飞的医药上市企 业。公司营业收入自上市以来连续保持正向增长，2025 年上半年，公司实现营 业收入 13.98 亿元，继续维持业绩的稳健增长。 围绕"国内+国际"、"原料+制剂"战略，2025 年上半年，公司持续推进产 能利用、市场开拓、产品研发及体系认证工作，取得积极进展。 在产能利用方面，公司持续推进上海司太立新制剂车间、海神 400 吨碘海醇 及 200 吨碘帕醇原料药车间、江西 300 吨碘佛醇车间等已建成产能的法规认证和 变更工作，2025 年上半年，海神 400 吨碘海醇原料药车间获得中国 NMPA 上市申 请批准通知书并通过 GMP 符合性认证。 在制剂市场开拓方面，公司持续推进国内外的客户开发工作。上半年，上海 司太立碘美普尔注射液和钆贝葡胺注射液成功中标新疆二十六省联盟药品集中 带量采购，展现了公司在产品研发、生产和质量管 ...